Evidence map›Paper›PMID 26714964›Full record

ArticleMolecular diagnosis & therapy2016

BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?

Timothy J Price, Carol Beeke, Amanda Rose Townsend, Louisa Lo, Roy Amitesh, Robert Padbury, David Roder, Guy Maddern, James Moore, Christos Karapetis

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Clinicopathological Significance ofJournal of Cancer · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Timothy J PriceDepartment of Medical Oncology, The Queen Elizabeth Hospital, Woodville Road, Woodville, SA, 5011, Australia. timothy.price@health.sa.gov.au.
Carol BeekeDepartment of Surgery, Flinders Medical Centre, Adelaide, SA, Australia.
Amanda Rose TownsendDepartment of Medical Oncology, The Queen Elizabeth Hospital, Woodville Road, Woodville, SA, 5011, Australia.
Louisa LoDepartment of Medical Oncology, The Queen Elizabeth Hospital, Woodville Road, Woodville, SA, 5011, Australia.
Roy AmiteshDepartment of Medical Oncology, Flinders Medical Centre, Adelaide, SA, Australia.
Robert PadburyDepartment of Surgery, Flinders Medical Centre, Adelaide, SA, Australia.
David RoderSchool of Population Health, University of South Australia, Adelaide, SA, Australia.
Guy MaddernDepartment of Surgery, The Queen Elizabeth Hospital, Adelaide, SA, Australia.
James MooreDepartment of Surgery, Royal Adelaide Hospital, Adelaide, SA, Australia.
Christos KarapetisDepartment of Medical Oncology, Flinders Medical Centre, Adelaide, SA, Australia.
Flinders Medical Centre · AUQueen Elizabeth Hospital · AUFlinders University · AURoyal Adelaide Hospital · AUUniversity of Adelaide · AUUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with metastatic colorectal cancer (mCRC) with BRAF mutation (BRAF MT) generally have a poorer prognosis. BRAF MT may also have implications for treatment strategy. Despite this, inclusion of BRAF in routine molecular testing varies. Here we report the frequency of BRAF reporting in the South Australian (SA) mCRC registry reflecting community practice, together with the survival outcomes based on mutation status.

methodsThe SA population-based mCRC registry was analysed to assess the number of patients where a BRAF MT result was available. The patient characteristics are reported and overall survival was analysed using the Kaplan-Meier method.

resultsOf the 3639 patients who have been entered in the registry, only 6.2% (227) have BRAF MT results available. Of the patients tested, the BRAF MT rate is 12.7%. The mutation rate was highest in rightsided primary; right colon 23 versus left colon 8.9% and rectum 7%. There was no significant difference in median age or male/female proportion. The median overall survival (mOS) for BRAF MT versus wild-type (WT) patients is 14.0 versus 32.9 months (p = 0.003). For patients who have chemotherapy (plus or minus surgery) the mOS is 14.6 months BRAF MT versus 36.1 months (p ≤ 0.001) WT. Liver or lung resection was performed on only 8% of the BRAF MT group versus 26.5% of the WT group.

conclusionResults in a population setting confirm our understanding that BRAF MT is more frequently right sided and of lower frequency in rectal cancer. Survival is lower for patients with mCRC that have BRAF MT, regardless of the therapy. BRAF testing is currently performed infrequently in an Australian setting despite its importance as a significant prognostic factor, and the implications for alternate therapeutic approaches.

Indexed as

AdultAgedAged, 80 and overAustraliaBevacizumabBiomarkers, TumorCamptothecinCapecitabineColorectal NeoplasmsFluorouracilGenetic TestingHumansIrinotecanLeucovorinMiddle AgedMutationBevacizumabBiomarkers, TumorBRAF protein, humanCamptothecinCapecitabineFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsOxaliplatinProto-Oncogene Proteins B-raf

Identifiers

PMID26714964
OpenAlexW2209385403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.